ADC Therapeutics SA (NYSE:ADCT – Free Report) – HC Wainwright cut their Q3 2025 earnings per share estimates for shares of ADC Therapeutics in a research note issued to investors on Thursday, October 16th. The consensus estimate for ADC Therapeutics’ current full-year earnings is ($1.69) per share. HC Wainwright also issued estimates for ADC Therapeutics’ Q4 2025 earnings at ($0.37) EPS and FY2025 earnings at ($1.62) EPS. Get ADC Therapeutics alerts:ADC Therapeutics (NYSE:ADCT – Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. ADC Therapeutics has a twelve month low of $1.05 and a twelve month high of $4.74.